Pharvaris N.V..
PHVS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Pharvaris N.V. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare diseases, specifically hereditary angioedema (HAE). Their primary focus is on developing oral bradykinin B2 receptor antagonists, including their lead product candidate, deucrictibant, fo...Show More
Better Health for All
20
Pharvaris is entirely focused on developing novel therapies for hereditary angioedema (HAE) and acquired angioedema, rare diseases that can be life-threatening.
1
Their lead product candidate, deucrictibant, is being developed for both acute on-demand treatment and long-term prevention of HAE attacks.
2
Clinical trials show deucrictibant provides faster symptom relief and resolution compared to placebo and other approved drugs.
3
The company conducts its clinical trials in compliance with Good Clinical Practices (GCP) and requires approval from IRBs or Ethics Committees.
4
The RAPIDe-3 study enrolled 134 participants from 24 countries, including adolescents and adults, and was compliant with the Core Outcome Set recommended in the AURORA consensus.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Pharvaris N.V. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Pharvaris N.V. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Pharvaris N.V. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
40
The company's financial statements, including 100% of total assets, 100% of total expenses, and 100% of loss before tax, are covered by independent external audit.
1
Kind to Animals
-50
Pharvaris conducts extensive animal testing, including general toxicity studies up to 6 months in rats and 9 months in monkeys, as well as reproductive and developmental studies in rats and rabbits.
1
The company states that certain laws and regulations require pre- and nonclinical animal testing.
2
While a human bradykinin challenge model is used for pharmacodynamics, traditional animal assays dominate for safety and efficacy assessments.
3
The FDA requested an additional 26-week rodent toxicology study, which has been initiated.
4
The company uses 15,000–25,000 animals per year, including rats, rabbits, and monkeys, for its studies.
No War, No Weapons
0
No information regarding Pharvaris N.V.'s association with arms manufacturing, military contracts, or conflict facilitation was found in the provided articles.
1
The articles focus solely on the company's biopharmaceutical activities, specifically the development of treatments for hereditary angioedema (HAE).
2
Planet-Friendly Business
-20
The company has no reported environmental compliance violations, fines, or regulatory actions mentioned across the provided articles.
1
This indicates an absence of negative environmental compliance events.
Respect for Cultures & Communities
0
No evidence available to assess Pharvaris N.V. on Respect for Cultures & Communities.
Safe & Smart Tech
10
Pharvaris outlines data processing addendum provisions to ensure compliance with various international and US data protection laws.
1
This includes specific requirements for data transfers in multiple jurisdictions such as Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, the European Economic Area (EEA), Israel, Singapore, Switzerland, and the United Kingdom, emphasizing the use of Standard Contractual Clauses (SCCs) where applicable.
2
The company also addresses US data protection laws, including the California Consumer Privacy Act (CCPA), Colorado Privacy Act, Connecticut Act Concerning Data Privacy, Utah Consumer Privacy Act, Virginia Consumer Data Protection Act, Executive Order 12333, and the Foreign Intelligence Surveillance Act (FISA).
3
Zero Waste & Sustainable Products
0
No specific, concrete data points were found across the provided articles to assess Pharvaris N.V. against any of the 'Zero Waste & Sustainable Products' KPIs.
1
The articles either explicitly state 'no specific data' for the company regarding these metrics or provide general industry information not attributable to Pharvaris N.V.
2